Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis.

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic dysregulation is implicated in various cancers, including Ewing sarcoma (EwS).
• The specific epigenetic mechanisms driving oncogenic signaling and treatment response in EwS are not fully understood.

Purpose of the Study:

• To elucidate the epigenetic networks essential for Ewing sarcoma tumor progression and therapeutic response.
• To identify key regulators of oncogenic signaling and protein synthesis in EwS.

Main Methods:

• Utilized epigenetics- and complex-focused CRISPR screens to identify essential genes in EwS.
• Performed CRISPR gene body scans to pinpoint critical functional residues.
• Investigated the effects of RUVBL1 suppression on MYC signaling, histone acetylation, and protein synthesis.
• Evaluated combination therapy strategies in EwS models.

Main Results:

• RUVBL1, a component of the NuA4 complex, was identified as essential for EwS tumor growth.
• RUVBL1 suppression led to reduced tumor growth, decreased histone H4 acetylation, and diminished MYC signaling.
• RUVBL1 was found to regulate MYC chromatin binding and MYC-driven EEF1A1 expression, impacting protein synthesis.
• Synergistic effects were observed between RUVBL1 suppression and MYC inhibition in EwS models.

Conclusions:

• RUVBL1 plays a critical role in maintaining oncogenic signaling and tumor progression in Ewing sarcoma.
• Targeting the interplay between chromatin remodelers, MYC, and protein translation offers a novel therapeutic strategy for EwS.
• Combination therapy involving RUVBL1 suppression and MYC inhibition demonstrates therapeutic potential for Ewing sarcoma.